Related Experiment Video
Updated: Feb 4, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Primary Nocturnal Enuresis: A Novel Therapeutic Strategy With Higher Efficacy
Michel Jabbour1, Rawad Abou Zahr1, Marielle Boustany2
1University of Balamand, Saint George Hospital University Medical Center, Division of Urology, Beirut 1100 2807, Lebanon.
Insights
A new protocol combining desmopressin and propiverine significantly improved treatment success and reduced relapse rates for children with primary nocturnal enuresis. This approach offers higher efficacy and better long-term outcomes for bedwetting management.
Area of Science:
- Pediatrics
- Urology
- Clinical Pharmacology
Background:
- Primary nocturnal enuresis affects a significant number of children, impacting their quality of life.
- Existing treatments for nocturnal enuresis have varying efficacy and relapse rates.
- A need exists for optimized treatment protocols to enhance outcomes.
Purpose of the Study:
- To introduce and evaluate a novel treatment protocol for primary nocturnal enuresis.
- The objective was to increase treatment efficacy and decrease the rate of relapse.
- To assess the effectiveness of a combination therapy approach.
Main Methods:
- A prospective study involving 185 children diagnosed with nocturnal enuresis (age >5 years).
- Participants received a combination therapy of desmopressin (120 µg MELT) and propiverine (7.5 mg), with dosage adjustments based on response.
- Outcomes were assessed using International Children Continence Society (ICCS) definitions over a mean follow-up of 62 months.
Main Results:
- One hundred twenty-two patients met inclusion criteria, with a median age of 9 years.
- The protocol achieved an 87% complete success rate, with a 13% failure and relapse rate.
- Higher success rates (92.7%) were observed with 120 µg desmopressin maintenance therapy compared to higher doses (65%).
Conclusions:
- Combination therapy with a structured withdrawal protocol demonstrates superior efficacy in treating primary nocturnal enuresis.
- This protocol leads to higher success rates and reduced relapse in pediatric patients.
- The findings support the adoption of this structured combination therapy for improved bedwetting management.
Objective:
To introduce a new protocol for patients with primary nocturnal enuresis to increase efficacy of treatment and decrease relapse rate.
Methods:
A prospective study was done on 185 children diagnosed with nocturnal enuresis between the years 2007 and 2014. Inclusion criteria consisted of age >5 years, monosymptomatic enuresis or non-monosymptomatic enuresis, strict abidance by the protocol, and follow-up >24 months. Exclusion criteria consisted of secondary enuresis, poor compliance to protocol, and neurogenic bladder. Participants were started on combination therapy of desmopressin 120 µg (MELT formula) once per day and propiverine 7.5 mg twice per day, which were then adjusted as per their response to therapy and our designed protocol. Outcome was defined as per the International Children Continence Society (ICCS) latest definitions.
Results:
One hundred twenty-two patients satisfied the inclusion criteria and were included in the study with a median age of 9 years (range 5-19 years). The mean follow-up time was 62 months (range 25-114 months). Our protocol showed an overall complete success of 87% with failure and relapse of 13%. The success rate of patients needing 120 µg desmopressin as maintenance therapy to achieve dryness was 92.7% as compared to 65% success in patients needing a higher dose of desmopressin to achieve dryness (P < .05). Age, gender, and type of primary nocturnal enuresis had no effect over success (all P > .05).
Conclusion:
Adopting combination therapy along with structured withdrawal as per our protocol showed higher success rates and lower relapses in primary nocturnal enuretic children.
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
09:19High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
Related Concept Videos
Self-Efficacy
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Persuasion Strategies
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Microorganisms in Medicine and Therapeutics